Who We Are
Biotle is a research-driven biotechnology company developing next-generation antibody medicines for oncology and autoimmune diseases. Our proprietary TriME® Platform enables bi- and tri-specific designs that precisely coordinate immune responses while maintaining a strong safety margin.
Our Focus
Developing transformative, mechanism-driven therapeutics that redefine standards of care for patients with cancer and autoimmune diseases.
Our Platform - TriME®
Modular bi/tri-specific architecture anchored by a fully human CD3ε arm with controllable affinity, optimized for potent, durable activity and reduced off-target activation. More about TriME®.
What Makes Biotle Different
- Addressing unmet medical needs: We focus on patient populations in oncology and autoimmune diseases where existing treatments are inadequate or unavailable, aiming to deliver meaningful new options.
- Mechanism-driven innovation: Our programs are built on deep understanding of disease biology and immune pathways, enabling us to design antibody therapeutics that intervene at critical points to achieve targeted, effective, and safer outcomes.
- Differentiated products: Using our proprietary TriME® Platform and expertise in bi-/tri-specific design, we create therapies with distinctive attributes — from unique target combinations to superior safety, efficacy, and convenience — that set them apart from competing treatments.
Our Positioning: Differentiated on Validated Targets
We build highly differentiated medicines on validated targets: we de‑risk biology and focus resources on design choices that truly move clinical value and market adoption.
- Lower target risk: Stand on solid biology and optimize structure and function to increase program success and capital efficiency.
- Faster development path: Clearer regulatory dialogue and trial design make IND/clinical execution more predictable.
- Stronger commercial fit: Differentiation in efficacy, safety, and convenience is tangible for physicians and patients, accelerating uptake.
Therapeutic Areas
Oncology
We design tumor-targeted engagers and antibody formats intended to overcome resistance and broaden responses across solid and hematologic malignancies.
Autoimmune Diseases
Our programs aim to selectively recalibrate dysregulated immune pathways, with the goal of durable disease control and improved quality of life.
Message from the CEO
At Biotle, our vision is bold and simple: harness immune biology with precision to change the trajectory of cancer and autoimmune disease. With our TriME® Platform, we can purpose-build bi- and tri-specific antibodies that combine potency with safety and manufacturability.
We are expanding a differentiated pipeline, forging strategic partnerships, and investing in quality from discovery through GMP — so promising science can reach the clinic and, ultimately, patients who need new options.
Thank you for supporting Biotle as we work to deliver best-in-class therapies that raise the bar for efficacy, safety, and convenience.
-Dr Jiansong Yang, Founder & CEO